eli lilly glp-1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs Vitamins & Supplements flavor:60 Count GIPR/GLP-1R dual agonist therapies

eli lilly glp-1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs Vitamins & Supplements flavor:60 Count GIPR/GLP-1R dual agonist therapies

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application - PMC

Research and development of safe and effective anti-obesity pharmacotherapies is urgently needed considering the current obesity epidemic

Vitamins & Supplements

flavor:60 Count

Not before 2034